Amgen (AMGN) Total Current Liabilities (2009 - 2026)
Amgen (AMGN) posted quarterly Total Current Liabilities of $25.0 billion for Q1 2026, up 8.46% year-over-year from $23.0 billion in Q1 2025, and down 2.1% quarter-over-quarter from $25.5 billion in Q4 2025.
Amgen (AMGN) Total Current Liabilities (2009 - 2026) Analysis & Trends
Amgen's Total Current Liabilities history runs 18 years deep, the most recent figure standing at $25.0 billion for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 8.46% year-over-year to $25.0 billion; the TTM figure through Mar 2026 stood at $25.0 billion (up 8.46% YoY), while the FY2025 annual figure was $25.5 billion, up 10.35% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $25.0 billion, down from $25.5 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $25.5 billion in Q4 2025, with the low at $12.6 billion in Q2 2022.
- The 5-year median for Total Current Liabilities is $19.7 billion (2024), against an average of $19.0 billion.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities declined 13.49% in 2022, then jumped 38.68% in 2024.
- Amgen's Total Current Liabilities stood at $15.7 billion in 2022, then increased by 17.24% to $18.4 billion in 2023, then grew by 25.59% to $23.1 billion in 2024, then climbed by 10.35% to $25.5 billion in 2025, then slipped by 2.1% to $25.0 billion in 2026.
- Business Quant data shows AMGN's Total Current Liabilities at $25.0 billion in Q1 2026, $25.5 billion in Q4 2025, and $21.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.50 Bn |
| Mar 31, 2026 | 24.96 Bn |
| Dec 31, 2025 | 25.49 Bn |
| Sep 30, 2025 | 21.79 Bn |
| Jun 30, 2025 | 20.48 Bn |
| Mar 31, 2025 | 23.01 Bn |
| Dec 31, 2024 | 23.10 Bn |
| Sep 30, 2024 | 20.31 Bn |
| Jun 30, 2024 | 21.52 Bn |
| Mar 31, 2024 | 19.71 Bn |
| Dec 31, 2023 | 18.39 Bn |
| Sep 30, 2023 | 16.95 Bn |
| Jun 30, 2023 | 17.10 Bn |
| Mar 31, 2023 | 14.22 Bn |
| Dec 31, 2022 | 15.69 Bn |
| Sep 30, 2022 | 14.33 Bn |
| Jun 30, 2022 | 12.62 Bn |
| Mar 31, 2022 | 12.89 Bn |
| Dec 31, 2021 | 12.18 Bn |
| Sep 30, 2021 | 14.84 Bn |